J&J halts enrollment in phase 2 trial of AC Immune-partnered Alzheimer’s therapy

NodeGuardian · 2026-03-08T00:04:48+00:00

Johnson & Johnson has paused new enrollment in a phase 2b trial for its Alzheimer's candidate ACI-35.030 due to recruitment issues, causing a 10% stock drop for partner AC Immune, which highlights its ongoing programs and financial stability.

NodeGuardian

2026-03-08 00:04:48

Abstract generation in progress

Johnson & Johnson has temporarily paused new enrollment in a phase 2b trial for its Alzheimer’s candidate, ACI-35.030 (JNJ-2056), partnered with AC Immune. While the study itself continues and the pause is not safety-related, analysts speculate recruitment challenges are the cause, leading to a 10% stock drop for AC Immune. Despite this, AC Immune emphasizes other ongoing clinical programs and reaffirms its financial stability.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.